¿Sabías qué?
El medicamento genérico puede reducir hasta un 60% el precio del medicamento innovador »
El medicamento genérico se diferencia porque en su etiqueta aparece el principio activo y las siglas EFG »
El medicamento genérico tiene la misma calidad, eficacia y seguridad que el medicamento innovador »
El medicamento genérico y el de marca son intercambiables ya que ambos contienen el mismo principio activo »
El primer genérico que se comercializó en España fue el AZT o Zidovudina para el tratamiento del VIH »
En la Sanidad Pública cada vez se hace más uso de los medicamentos genéricos »
Las siglas EFG significan Equivalente Farmacéutico Genérico »
Los genéricos tienen un coste menor porque no se ha invertido en investigación para su descubrimiento »
English VersionRSS

EGA welcomes EMA guideline for biosimilar

29/11/2010 - EGA welcomes EMA guideline for biosimilar monoclonal antibodies as well-balanced and beneficial to patients.

Leer más:

Europe’s generic medicines companies welcome MEPS vote on industry information to patients

24/11/2010 - Europe’s generic medicines companies welcome MEPS vote on industry information to patients

Leer más:

Interview with The European Generic Medicines Association

17/11/2010 - Interview with The EuropeanGeneric Medicines Association

Leer más:

Guía sobre medicamentos biosimilares

17/11/2010 - Guía sobre medicamentos biosimilares

Leer más:

Generic and biosimilar medicines offer quality therapies and sustainable healthcare in the face of an ageing population

17/11/2010 - Generic and biosimilar medicines offer quality therapies and sustainable healthcare in the face of an ageing population

Leer más:

EGA pays tribute to EMA executive director Thomas Lönngren during 3rd EMA-EGA info day

10/11/2010 - EGA pays tribute to EMA Executive Director Thomas Lönngren during 3rd EMA-EGA Info Day

Leer más:

EGA vision 2015, the way forward for a more efficient regulatory environment for generic and biosimilar medicines

27/10/2010 - EGA vision 2015, the way forward for a more efficient regulatory environment for generic and biosimilar medicines

Leer más:

Meeting the European challenge for the national drug regulatory agencies and the generic medicines industry

30/09/2010 - Meeting the European challenge for the national drug regulatory agencies and the generic medicines industry

Leer más:

EGA calls for a workable guideline for biosimilar monoclonal antibodies and a consistent scientific global approach towards biosimilar medicines

02/09/2010 - EGA calls for a workable guideline for biosimilar monoclonal antibodies and a consistent scientific global approach towards biosimilar medicines

Leer más:

ECJ decision helps to ensure patient access to generic medicines

01/07/2010 - ECJ decision helps to ensure patient access to generic medicines

Leer más:

Only a sustainable generic medicines industry will maximise healthcare systems benefits in Europe

03/06/2010 - Only a sustainable generic medicines industry will maximise healthcare systems benefits in Europe

Leer más:

3rd EGA Bioequivalence Forum in London continues successful cooperation with the EU medicines authorities on EU guidelines

01/06/2010 - 3rd EGA Bioequivalence Forum in London continues successful cooperation with the EU medicines authorities on EU guidelines

Leer más:

Open letter to the Spanish Health and Social Policy Minister: price cuts must be followed by increase in patient access to generic medicines

06/05/2010 - Open letter to the Spanish Health and Social Policy Minister: price cuts must be followed by increase in patient access to generic medicines

Leer más:

EGA welcomes Committee adoption of falsified medicines and pharmacovigilance reports by MEPS

27/04/2010 - EGA welcomes Committee adoption of falsified medicines and pharmacovigilance reports by MEPS

Leer más:

EU must back generic medicines to safeguard the future of healthcare

25/03/2010 - EU must back generic medicines to safeguard the future of healthcare

Leer más:

IMS report highlights importance of generic medicines industry sustainability for the EU

23/03/2010 - IMS report highlights importance of generic medicines industry sustainability for the EU

Leer más:

EGA seeks urgent patent system reform and welcomes follow up to the sector inquiry

11/03/2010 - EGA seeks urgent patent system reform and welcomes follow up to the sector inquiry

Leer más:

MEPS launched discussion on new controls of active pharmaceutical ingredients (APIS)

03/03/2010 - MEPS launched discussion on new controls of active pharmaceutical ingredients (APIS)

Leer más:

EGA calls for improved regulatory framework with vision 2015 to create a stronger European Generic Medecine industry and increased patient access to affordable healthcare.

21/01/2010 - EGA calls for improved regulatory framework with vision 2015 to create a stronger European Generic Medecine industry and increased patient access to affordable healthcare.

Leer más:

Keep in mind the objectives of the EC Pharmacovigilance legislative proposals: improving the EU Pharmacovigilance System & Cutting Red Tape.

21/01/2010 - Keep in mind the objectives of the EC Pharmacovigilance legislative proposals: improving the EU Pharmacovigilance System & Cutting Red Tape.

Leer más:

Está aquí: Home EGA 2010